Uptravi
My Prescription
Payment
Select pharmacy
$25,010.44
Print or send this coupon to your phone
AlbertsonsPowered byAbout Uptravi
Drug Details
Selexipag, marketed under the name Uptravi, is a medication used to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the lungs. Its primary purpose is to slow down the progression of PAH and reduce the risk of hospitalization. Selexipag functions as a prostacyclin agonist, mimicking a natural chemical in the body to relax the blood vessels in the lungs. This action decreases lung blood pressure, improves blood flow, and enhances the heart's ability to pump efficiently, thereby increasing oxygen supply, making breathing easier, and improving exercise capacity. The medication is available in tablet form, taken orally twice daily, and as an intravenous injection for those unable to take it orally. Common side effects include headache, diarrhea, and nausea. Always consult a healthcare professional before starting any new medication.
Price history for Uptravi
60 Tablets, 1000MCG
Average retail price for Uptravi
Average SaveHealth price for Uptravi
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Uptravi dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 100MCG | 140 Tablets | $37,521.11 | $268.01 |
| 150MCG | 140 Tablets | $37,521.11 | $268.01 |
| 200MCG | 60 Tablets | $16,085.05 | $268.08 |
| 200MCG | 140 Tablets | $37,521.11 | $268.01 |
| 400MCG | 60 Tablets | $25,010.44 | $416.84 |
| 600MCG | 60 Tablets | $25,010.44 | $416.84 |
| 800MCG | 60 Tablets | $25,010.44 | $416.84 |
Uptravi FAQs
If a patient stops taking UPTRAVI (selexipag) suddenly, it may lead to a worsening of their pulmonary arterial hypertension (PAH) symptoms. It is important for patients to consult their healthcare provider before making any changes to their medication regimen, as the provider can offer guidance on how to safely discontinue or adjust the medication if necessary.
The cost of UPTRAVI can be considered high, as it is a specialized medication used for the treatment of pulmonary arterial hypertension. The price can vary based on factors such as dosage, insurance coverage, and pharmacy location. Patients are encouraged to check with their healthcare provider or insurance company for specific cost information and potential financial assistance programs.
Uptravi is not classified as a controlled substance. It is a medication used to treat pulmonary arterial hypertension.
Weight loss is not commonly reported as a side effect of UPTRAVI (selexipag). However, patients may experience other side effects, and any unexpected changes in weight should be discussed with a healthcare provider to rule out any underlying issues or to adjust treatment if necessary.
UPTRAVI is used for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization. It works by relaxing and widening the blood vessels in the lungs, which helps to lower blood pressure and improve the ability to exercise.